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A B S T R A C T
The eﬀect of vitamin D supplementation on growth of fetal bones during pregnancy is unclear. The aim of this
study was to assess the eﬀect of low dose vitamin D supplementation during pregnancy on bony anthropometric
aspects of the fetus. In this prospective randomized trial, 140 patients were divided into two equally matched
groups according to age, 25(OH)D level, exercise, and dietary intake. Then 1000 IU per day vitamin D sup-
plement was given to the intervention group while the control group received placebo. Then crown-rump length
(CRL) and femur length (FL) during the ﬁrst trimester and humerus and femur lengths as well as their proximal
metaphyseal diameter (PMD), midshaft diameter (MSD) and distal metaphyseal diameter (DMD) in the second
and third trimester were measured using ultrasonography technique. Finally, no signiﬁcant diﬀerence was ob-
served for CRL (p=0.93). Although FL was not statistically signiﬁcant in the ﬁrst trimester (p=0.54), its
measurement in the intervention group and the control group in the second (28.87 ± 2.14 vs. 26.89 ± 2.08;
p≤0.001) and the third (65.31 ± 2.17 vs. 62.85 ± 1.94; p≤0.001) trimesters was signiﬁcantly diﬀerent.
Femoral PMD, MSD, and DMD measurement increased more in the intervention group in comparison with the
control group with P values< 0.05. HL measurement in the intervention group and the control group in the
second (28.62 ± 1.94 vs. 27.23 ± 2.08; p≤0.001) and the third (61.29 ± 2.84 vs. 59.85 ± 1.79; p≤0.001)
trimesters revealed signiﬁcant diﬀerences. Humeral PMD, MSD, and DMD measurement increased in the in-
tervention group in comparison with the control group with P values< 0.001 for all. It is suggested to prescribe
low dose vitamin D (1000 IU per day) from early pregnancy with possible increment in length and diameter of
femur and humerus bones of the fetus.
1. Introduction
Vitamin D as one of the main elements has a signiﬁcant role in
regulating calcium and phosphorus in the body [1–3]. Vitamin D eﬀect
on cell diﬀerentiation and maturation [4,5], immunity [6], improved
quality of life [7], autoimmune diseases such as thyroiditis, cancers and
cardiovascular diseases have been proven [8–10]. Vitamin D can be
acquired through diet or sun exposure. Its deﬁciency is reported to be
common amongst people, especially pregnant women [11–13].
One of the challenging issues for the role of vitamin D supple-
mentation during pregnancy is its eﬀect on the newborn anthropometry
measurements such as birth weight, head circumference and long bone
length [14–17]. Based on the literature review, with regard to the im-
pact of vitamin D on fetus, there are controversies on vitamin D
deﬁciency consequences on the estimated fetal weight [18–21], growth
retardation [18–20,22,23], and femur length (FL) [24–26] and crown-
rump length (CRL) [27]. Although several observational studies showed
the eﬀect of vitamin D during pregnancy on anthropometric fetal fea-
tures [24,26–28], as far as we know, no randomized clinical trial has
been performed to describe vitamin D supplementation eﬀect on the
fetal bone growth [29]. High prevalence of vitamin D deﬁciency in
addition to loss of a randomized study motivated us to determine and
assess the impact of vitamin D supplementation on fetal anthropometric
measurements in this clinical prospective double-blind randomized
survey.
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2. Materials and methods
2.1. Study design and data collection
This prospective randomized trial was performed on early pregnant
women under antenatal clinic care of Hafez hospital, the main center
for perinatology in Shiraz, in the south of Iran from June 2017 to
September 2017. Pregnant women were referred to the obstetric clinic
after 2 weeks of menstrual retardation as they were previously educated
at preconception counselling. Inclusion criteria were 20–35-years-old
healthy primigravida pregnant Iranian woman with normal body mass
index (BMI), without any comorbidities such as diabetes mellitus,
thyroid disease, liver disease, or mental illnesses. Exclusion criteria
were smoking, drug abuse, alcohol consumption, multiple pregnancy,
congenital anomaly or chromosomal abnormality, and cases that did
not accept to participate or did not sign the informed consent form.
Moreover, during the survey, complicated pregnancies such as hy-
pertension, preeclampsia, premature rupture of membrane, severe va-
ginal bleeding, and threatened course of labor were excluded from the
study. Informed consent was obtained from all individual participants
included in the study. This study was approved by the local Ethics
Committee of Shiraz University of Medical Sciences review board (code:
IR.SUMS.MED.REC.1396.78). This research was also registered at
Iranian Registry of Clinical Trials (code: IRCT 20140317017034N6).
The sample size was set at 120 individuals considering α: 05 and
power of 80%. To increase the reliability and power of the study, we
initiated the study with 140 pregnant women. Block randomization
(size of each block=4) was performed to divide participants into two
groups of 70 each, using random allocation software.
2.2. Sampling and laboratory analysis
First, a 10 cc of peripheral blood sample was taken with routine
work-up for pregnancy before any supplementation was used. It was
stored at −80 °C after being centrifuged (1000×g for 15min) until
analysis at the end of collecting sonography data from all cases [30].
25(OH)D level was quantiﬁed using Roche-electrochemiluminescence
(ECL) [31] technology by the immunoassay analyzer Cobas e 411
(Roche Diagnostics, Mannheim, Germany). The accuracy of the process
was monitored by lab quality control staﬀ. The lab technicians were
blinded to the group allocation. The inter- and intra-assay coeﬃcients
of variation were< 15%. Based on serum 25(OH)D level at the end of
the study, three groups were deﬁned; vitamin D deﬁcient (< 20 ng/
mL), insuﬃcient (20–30 ng/mL) and suﬃcient (> 30 ng/mL) in order
to conﬁrm intervention and control groups to be matched in the aspect
of mean 25(OH)D level and distribution in each group.
2.3. Clinical trial
After randomly dividing the patients into two groups as previously
mentioned, the control group received placebo (same color and shape
capsules containing starch) while the intervention group received
1000 IU of vitamin D (Jalinous Pharmaceutical Company, Tehran, Iran)
daily, starting two weeks after menstrual retardation. The pills were
continued till the last sonography at 34 weeks of gestational age. Both
study groups received routine prenatal care. Monitoring of vitamin D
pills or placebo consumption in both groups was done during each visit
for pregnancy care.
2.4. Sonographic study
Synchronous to each trimester sonography, all sonographic data
collection was done by an expert sonographer who was blinded to the
group allocation. CRL and FL were measured by the standard technique
with standard view at 13 weeks of gestational age. Then, at 18 and
34weeks of gestational age, in addition to measuring humerus length
(HL) and FL, proximal metaphyseal diameter (PMD), mid shaft dia-
meter (MSD) and distal metaphyseal diameter (DMD) of humerus and
femur (Fig. 1) were measured by the same expert sonographer, using
Voluson E8 Sonography machine (General Electronic Healthcare
Fig. 1. Sonographic measurement of fetus long bone including D1: proximal metaphyseal diameter (PMD), D2: mid shaft diameter (MSD), D3: distal metaphyseal
diameter (DMD) and D4: bone length.
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Technologies, Wisconsin, USA, seral number D 13412). To measure
bone features and criteria variables coronal view was used [25,29].
2.5. Statistical analysis
Descriptive statistics for qualitative and quantitative variables were
reported as frequency (%) and mean ± SD. To compare groups, Chi-
square or independent t-test was performed and paired t-test was used
for group comparison. All the statistical analyses were performed in
SPSS 19.0 (SPSS Inc., Chicago, IL, USA). P < 0.05 was considered to be
statistically signiﬁcant.
3. Results
Finally, there were 68 pregnant women in the intervention group
and 62 in the control group (Fig. 2). During the study, two individuals
from the intervention group were excluded (premature labor pain in
one and the other one decided not to continue her participation). Also 8
from the control group could not complete the project (2 not willing to
continue, 1 abortion, 1 preeclampsia, 2 premature rupture of mem-
brane, 1 insulin-dependent gestational diabetes, and one due to severe
vaginal bleeding and abruption of placenta).
Mean age of participants in the intervention group was
27.0 ± 3.8 years and in the control group was 26.5 ± 3.2 years,
which was not statistically signiﬁcant (P=0.41). Although amount of
exercise in the intervention group was higher than control, Chi-square
test showed that the observed diﬀerence was not statistically signiﬁcant
(20.6% vs. 9.7%, P=0.09). Moreover, independent t-test revealed that
the two groups were the same in term of 25(OH)D level as a whole
(P=0.98) (Table 1). Also these groups were matched based on the
number of cases with diagnosis of vitamin D deﬁciency, vitamin D in-
suﬃciency and vitamin D suﬃciency by checking the frozen samples at
the end of survey (Table 2).
No signiﬁcant diﬀerence was observed for CRL with mean ±
standard deviation in the intervention group vs. the control
(65.4 ± 5.3 versus 65.3 ± 3.9; P=0.93).
Fetal FL in the ﬁrst trimester for the intervention group was
9.92 ± 1.11 vs. 9.80 ± 1.17 for the control, which was not
Fig. 2. CONSORT ﬂow diagram for this randomized, double-blinded, placebo controlled clinical trial of the use of Vitamin D in pregnant women.
Table 1
Comparison of demographic characteristics of the two groups.
Characteristics Intervention group
(n=68)
Control group
(n=62)
P-value
Mean ± SD Mean ± SD
Age 27.0 ± 3.8 26.5 ± 3.2 0.41
25(OH)D level 18.6 ± 9.8 18.6 ± 9.0 0.98
Exercise No 54 (79.4) 56 (90.3) 0.09
Yes 14 (20.6) 6 (9.7)
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statistically signiﬁcant (P=0.54), but fetal FL of the intervention group
at the second (P < 0.001) and third trimester (P < 0.001) was sig-
niﬁcantly higher than controls (Table 3). Our results also showed that
PMD-FL, MSD-FL and DMD-FL were signiﬁcantly higher in the inter-
vention group at the 2nd and 3rd trimesters (P < 0.001) (Fig. 3).
Fetal HL at the second (28.62 ± 1.94 vs. 27.23 ± 2.08,
P < 0.001) and third (61.29 ± 2.84 vs. 59.85 ± 1.79, P < 0.001)
trimesters were signiﬁcantly higher in the intervention group in com-
parison with the control (Fig. 4), but the diﬀerence was not statistically
signiﬁcant (32.68 ± 3.00 vs. 32.62 ± 2.78, P=0.91). In addition,
amounts of growth in PMD-HL, MSD-HL and DMD-HL were sig-
niﬁcantly higher in the intervention group (P < 0.001, Table 3).
4. Discussion
The prevalence of vitamin D deﬁciency and insuﬃciency is high in
several parts of the world, especially in the Middle Eastern region of
Asia [32–34]. Several factors such as genetics, demographics, BMI and
skin color, lifestyle variables including smoking, sunscreen usage and
clothing, latitude and location of living have an important role in the
25(OH)D level [11,30,35]. The problem of vitamin D deﬁciency might
be aggravated during winter due to reduced sun exposure [36,37]. We
selected participants during the summer season with normal BMI from a
similar race and ethnicity to overcome the above aﬀecting factors.
Vitamin D deﬁciency could result in unfavorable pregnancy out-
comes amongst mothers including preeclampsia, gestational diabetes
mellitus, premature rupture of membrane and premature labor pain
with increased rate of cesarean section [1,18,20,36,38–40]. Based on
our study, one participant from the case group (1.4%) suﬀered pre-
mature labor pain while 6 individuals (8.5%) had obstetric complica-
tions such as abortion, preeclampsia, premature rupture of membrane,
insulin-dependent gestational diabetes and severe vaginal bleeding
with abruption of placenta. Besides, negative eﬀects of vitamin D de-
ﬁciency on the fetus were reported such as neural tube defects, brain
neurodevelopment, smaller head circumference, intrauterine growth
retardation, small for gestational age and macrosomia
[5,19,22,38,39,41]. On the other hand, eﬀects of suﬃcient vitamin D
during pregnancy on child intelligence, psychological health and car-
diovascular system were reported [4]. Therefore, more randomized
control studies are warranted to make clear the eﬀect of vitamin D
supplementation on reducing pregnancy complications and neonatal
adverse outcome.
Deﬁnite recommended dose of vitamin D supplementation during
pregnancy is unclear [1]. Some authors recommended 25(OH)D
level> 50 nmol/L (20 ng/mL) while others agreed with 75 nmol/L
(30 ng/mL) during pregnancy [1,42,43]. Kisa et al. stated that maternal
serum 25(OH)D levels< 10 ng/mL is a risk factor for adverse preg-
nancy outcomes [38]. World Health Organization (WHO) recommends
400–600 IU of vitamin D daily during pregnancy while some in-
vestigators believe that it cannot establish the optimal level of 25(OH)D
level through circulation [1,44,45]. Dawson-Hughes et al. re-
commended 1000–1600 IU per day to aﬀord pregnancy demand of vi-
tamin D [42]. Some researchers do not agree to prescribe 2000 IU, since
they believe that it does not improve anthropometric measures of a
newborn [9,45], Others agreed that high dose of 4000 IU is eﬀective in
reducing maternal and neonatal complications of pregnancy [1,44–46].
To perform this study, 1000 IU vitamin D was prescribed with positive
eﬀects on both femur and humerus features criteria including length
and diameters during the second and third trimester of pregnancy
(P < 0.05). Although high dose of vitamin D is mentioned to be safe,
this randomized control trial study showed eﬀectiveness of low dose of
vitamin D on fetal bones to diminish the fear of toxicity and adverse
eﬀects of vitamin D. One factor in this outcome might be the season we
chose the patients and amount of sun exposure. Hence, the re-
commended dose of vitamin D supplementation to aﬀect fetal bone
might vary according to season, nationality, sun exposure and other
variables. More studies should be done to determine the deﬁnite dose of
vitamin D supplementation eﬀective for fetal bone improvement in
other regions in order to develop a national policy.
To clear the correlation between the ﬁrst trimester measurements
and 25(OH)D levels, Fernandez-Alonso et al. in a cohort study mea-
sured CRL as a variant of fetal growth [27]. In our randomized control
trial study, no correlation was found between the treated patients and
non-treated individuals measuring CRL (P=0.93) and the ﬁrst trime-
ster FL (p=0.54). Lack of correlation mentioned in the aforementioned
study and ours, might obscure the real eﬀect of 25(OH)D level or vi-
tamin D supplementation on the variables since the time of initiation of
the therapy was two weeks after menstrual retardation, which might be
too early to increase maternal serum 25(OH)D level and aﬀect the ﬁrst
Table 2
Serum level of 25(OH)D in the two groups.
Group p-value
Intervention Control
Suﬃcient Count 13 11 0.999
% within Group 19.1% 17.7%
Insuﬃcient Count 9 12 0.475
% within Group 13.2% 19.4%
Deﬁcient Count 46 39 0.585
% within Group 67.6% 62.9%
Table 3
Comparison of diﬀerent variables between the two groups.
Variables Trimester Intervention group Control group p-Value
(Independent t-
test)Mean ± SD Mean ± SD
CRL First 65.4 ± 5.3 65.3 ± 3.9 0.93
NT First 1.6 ± 0.3 1.6 ± 0.3 0.93
FL First 9.92 ± 1.11 9.80 ± 1.17 0.54
Second 28.87 ± 2.14 26.89 ± 2.08 <0.001
Change 18.94 ± 2.40 17.09 ± 2.69 <0.001
p-Value (paired t-test) < 0.001 <0.001
FL Second 28.87 ± 2.14 26.89 ± 2.08 <0.001
Third 65.31 ± 2.17 62.85 ± 1.94 <0.001
Change 36.44 ± 2.76 35.97 ± 3.15 0.36
p-Value (paired t-test) < 0.001 <0.001
PMD-FL Second 4.72 ± 0.67 4.17 ± 0.53 <0.001
Third 11.91 ± 1.02 10.00 ± 1.68 <0.001
Change 7.19 ± 1.17 5.82 ± 1.70 <0.001
p-Value (paired t-test) < 0.001 <0.001
MSD-FL Second 2.90 ± 0.48 2.62 ± 0.34 <0.001
Third 7.90 ± 1.12 6.56 ± 0.91 <0.001
Change 5.00 ± 1.18 3.95 ± 1.01 <0.001
p-Value (paired t-test) < 0.001 <0.001
DMD-FL Second 4.60 ± 0.64 4.21 ± 0.63 0.001
Third 10.05 ± 0.86 9.05 ± 1.20 <0.001
Change 5.46 ± 1.09 4.85 ± 1.37 0.006
p-Value (paired t-test) < 0.001 <0.001
HL Second 28.62 ± 1.94 27.23 ± 2.08 <0.001
Third 61.29 ± 2.84 59.85 ± 1.79 0.001
Change 32.68 ± 3.00 32.62 ± 2.78 0.91
p-Value (paired t-test) < 0.001 <0.001
PMD-HL Second 4.64 ± 0.64 4.06 ± 0.59 <0.001
Third 9.21 ± 0.65 7.92 ± 1.00 <0.001
Change 4.57 ± 0.74 3.86 ± 1.08 <0.001
p-Value (paired t-test) < 0.001 <0.001
MSD-HL Second 2.71 ± 0.41 2.46 ± 0.31 <0.001
Third 5.46 ± 0.79 4.52 ± 0.51 <0.001
Change 2.75 ± 0.88 2.06 ± 0.57 <0.001
p-Value (paired t-test) < 0.001 <0.001
DMD-HL Second 4.07 ± 0.45 3.61 ± 0.50 <0.001
Third 7.89 ± 0.93 6.81 ± 1.16 <0.001
Change 3.82 ± 0.94 3.20 ± 1.30 0.002
p-Value (paired t-test) < 0.001 <0.001
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trimester variables. More studies should be conducted to evaluate the
eﬀect of starting vitamin D supplementation prior to preconception.
Vitamin D is known as a major factor in the development of mus-
culoskeletal system. Mahon et al. in a cohort study, established the
correlation between maternal 25(OH)D level and distal metaphyseal
cross-sectional area and splaying index, deﬁned as FL/distal metaphy-
seal cross-sectional area, but not FL at 19 and 34weeks of gestational
age. They emphasized on the importance of vitamin D eﬀect on bone as
early as 19 weeks of gestational age [24]. Relationship between ma-
ternal 25(OH)D and PMD was displayed by another observational co-
hort study [25]. Walsh et al. presented the association between early
pregnancy maternal 25(OH)D and FL measured at 20 weeks in the
winter group. They reported correlation between maternal 25(OH)D at
28 weeks of gestational age and FL measurements at 34 weeks of
pregnancy [47]. In a cross sectional study by Lee et al., no correlation
was mentioned between maternal 25(OH)D and bone growth variables
such as FL and HL with the exception of growth velocity of biparietal
bone diameter [28]. In our study, we found bone features improvement
in both femur and humerus length and diameter in the intervention
group (P < 0.001 for all) after the second trimester, which is not in
line with some previous data [27,28]. One of the possible reasons for
this contrary may be this hypothesis that vitamin D deﬁciency is ef-
fective ﬁrst on the diameter of long bones followed by late eﬀect on
length of the long bones in fetal period. Therefore, vitamin D supple-
mentation might stimulate both length and diameter as shown in our
study (P < 0.001).
This study had several strength including being a randomized con-
trol trial to assess long bone measurements in both the intervention and
control groups at all trimesters of pregnancy at low dose. There were
several limitations such as 2D-ultrasonography, which cannot reveal
bone hormonal and chemical interactions. Moreover, interfering
acoustic shadow for determining boundaries of bones should be con-
sidered. We conducted the study during summer season in our country,
Iran, so more studies in diﬀerent seasons and worldwide are warranted
to establish the optimal dose of vitamin D to inﬂuence fetal long bones,
the time to initiate supplementation and other questions that may arise
need to be answered.
5. Conclusion
In conclusion, our study revealed that low dose vitamin D supple-
mentation (1000 IU daily) starting from early pregnancy could not
Fig. 3. Femoral length and diameter in both groups in the second and third trimester of pregnancy.
Fig. 4. Humeral length and diameter in both groups in the second and third trimester of pregnancy.
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aﬀect CRL and FL in the ﬁrst trimester, but it was able to improve all
features of femur and humerus including length and diameter in the
second and third trimesters. Since vitamin D deﬁciency prevalence is
high amongst pregnant women, vitamin D supplementation is re-
commended from early pregnancy if not before conception to improve
bone measures of the fetus. This fact might be important, especially in
societies that suﬀer from stunting or osteoporosis. Further studies are
necessary to elucidate the eﬀect of vitamin D supplementation on fetal
bone growth in diﬀerent parts of the world.
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